HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade war; now that we've seen positive news on President Trump talks with President Xi, the market has started to rally. One group of companies that had been hit pretty hard is biotech and healthcare. Today, we are highlighting biotech and healthcare opportunities that look like they are in position to benefit most from this rally.
One that could certainly go parabolic is Endonovo Therapeutics, Inc. (ENDV). The company has several non-invasive therapies tackling everything from pain management to degenerative joint diseases. The company just announced a deal that will add up to $10 million in working capital to their balance sheet which could amplify the company's already rapid growth. At its current price now is a perfect time to research ENDV.
We are highlighting: Endonovo Therapeutics, Inc. (ENDV), Sesen Bio, Inc. (SESN), Oragenics, Inc. (OGEN), Axovant Sciences Ltd. (AXON), and Sorento Therapeutics, Inc. (SRNE).
The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a CAGR of 18.0% for the period of 2017-2022. The aforementioned Endonovo Therapeutics, Inc. (ENDV) (Market Cap: $12.294M, Share Price: $0.0283), a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, has developed a therapy that could help lessen the pain without the kinds of side effects many other opioid alternatives have. Their non-invasive easy to use ORTHOHALO™ device delivers targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation.
The company just released a shareholder letter, in it there is a list of the company's latest accomplishments. The list below is impressive and is a big reason why the company is starting a major rally.
- Signing two marketing agreements with well-established medical device sales organizations
- Establishment and expansion of a rapidly growing sales department
- The completion of the purchase price to the seller of the SofPulse Technology
- The new Roma medical device is on schedule for release in Q1 of 2019
ENDV also announced an agreement with Azure Capital that will bring the company up to $10 Million for general corporate purposes, including working capital. This is a major development that could expedite the company's growth.
Start your research on ENDV.
Sesen Bio, Inc. (SESN) (Market Cap: $54.599M, Share Price: $0.7049) reported an update on their NeoCart regulatory pathway based on discussions with the FDA indicating that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.
Another company with Orphan Drug status like ENDV, Oragenics, Inc. (OGEN) (Market Cap: $28.844M, Share Price: $0.98), has been granted Fast Track designation with the U.S. Food and Drug Administration and orphan drug status in Europe (ENDV's is in the US) for its product AG013. It is an Intrexon Actobiotics therapeutic candidate formulated to deliver the therapeutic molecule, human Trefoil Factor 1, to the mucosal tissues in the oral cavity in a convenient oral rinsing solution.
Axovant Sciences Ltd. (AXON) (Market Cap: $153.697M, Share Price: $1.01) recently presented at the 37th Annual J.P. Morgan Healthcare Conference. Pavan Cheruvu, M.D., Chief Executive Officer, represented the company.
Sorento Therapeutics, Inc. (SRNE) (Market Cap: $263.826M, Share Price: $2.30) through their subsidiary Scilex Pharmaceuticals recently announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives. ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain.
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal consulting has agreed to receive 3 million restricted 144 shares as a signing bonus, and additionally receive $4,000 cash per month, and 1 million restricted 144 shares per month starting 8/23/18, this is a twelve-month agreement, and can be canceled at anytime by the issuer ENDV. All payments were made directly by Endonovo Therapeutics, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. ENDV was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Microcap Speculators